Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Tokyo Stock Exchange  >  Astellas Pharma Inc.    4503   JP3942400007

ASTELLAS PHARMA INC.

(4503)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector news

Astellas Pharma : Completes Acquisition of iota Biosciences

11/02/2020 | 06:54am EST

TOKYO - Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., 'Astellas') announced today that it has completed the acquisition of Iota Biosciences, Inc. ('iota'), a start-up company focused on the bioelectronics field, located in Berkeley, California, and iota has become a wholly owned subsidiary of Astellas as of U.S. Pacific Time October 29, 2020.

Under the Merger Agreement executed between Astellas and iota shareholders, Astellas paid approximately US$127.5 million to acquire all of the outstanding equity in iota that was not previously held by Astellas (Astellas through a U.S. subsidiary, was an investor in iota through its previous Series A Preferred Stock offering). In addition, iota's former shareholders (other than Astellas) will be eligible to receive additional payments of up to a total of approximately US$176.5 million upon achievement of predetermined milestones by iota within certain timeframes after completion of the transaction.

Astellas is also committing to spend a total of US$125 million over the next five years to fuel iota's aggressive expansion.

This acquisition is expected to accelerate Astellas' Rx+ business not only by expediting the Rx+ projects previously covered under the Research and Development Agreement signed between the parties in August 2019 but also by allowing exploration of other applications of iota's unique bioelectronics technology for new target diseases and developing new technologies.

At this point, Astellas intends to maintain the organization in California and to retain the iota Biosciences name.

Rx+ business

A business that leverages the expertise and knowledge of Astellas, which has been cultivated through its prescription drug (Rx) business, integrates innovative medical technology with cutting-edge technology in different fields, contributes to patients through Patient Journey (overall medical care, including diagnostic, preventive, therapeutic, and prognostic care), and creates new revenue streams separate from Astellas' core Rx products.

About Astellas

Astellas Pharma Inc. is a pharmaceutical company conducting business in more than 70 countries around the world. We are promoting the Focus Area Approach that is designed to identify opportunities for the continuous creation of new drugs to address diseases with high unmet medical needs by focusing on Biology and Modality. Furthermore, we are also looking beyond our foundational Rx focus to create Rx+ healthcare solutions that combine our expertise and knowledge with cutting-edge technology in different fields of external partners. Through these efforts, Astellas stands on the forefront of healthcare change to turn innovative science into value for patients.

Cautionary Notes Astellas

In this press release, statements made with respect to current plans, estimates, strategies and beliefs and other statements that are not historical facts are forward-looking statements about the future performance of Astellas. These statements are based on management's current assumptions and beliefs in light of the information currently available to it and involve known and unknown risks and uncertainties. A number of factors could cause actual results to differ materially from those discussed in the forward-looking statements. Such factors include, but are not limited to: (i) changes in general economic conditions and in laws and regulations, relating to pharmaceutical markets, (ii) currency exchange rate fluctuations, (iii) delays in new product launches, (iv) the inability of Astellas to market existing and new products effectively, (v) the inability of Astellas to continue to effectively research and develop products accepted by customers in highly competitive markets, and (vi) infringements of Astellas' intellectual property rights by third parties. Information about pharmaceutical products (including products currently in development) which is included in this press release is not intended to constitute an advertisement or medical advice.

Contact:

Tel: +81-3-3244-3201

Fax: +81-3-5201-7473

(C) 2020 Electronic News Publishing, source ENP Newswire

All news about ASTELLAS PHARMA INC.
01/14ACTINIUM PHARMACEUTICALS : and Astellas Announce Research Collaboration Focused ..
AQ
01/06ASTELLAS PHARMA INC. : - FDA Accepts for Priority Review the New Drug Applicatio..
AQ
2020ASTELLAS PHARMA : FDA Lifts Clinical Hold for Audentes Therapeutics' AT132 Trial
MT
2020ASTELLAS PHARMA : Reports XOSPATA in Combination with Azacitidine Did Not Meet E..
AQ
2020ASTELLAS PHARMA : Supports Recommendations of Task Force on Climate-related Fina..
AQ
2020ASTELLAS PHARMA INC. : - Expansion of the Domestic Logistics Platform for Pharma..
AQ
2020VIATRIS : Astellas and Viatris Announce Termination of Co-promotion, Succession ..
AQ
2020Japan shares slip for third day; all eyes on U.S. stimulus debate
RE
2020Japanese shares slip back as investors look to U.S. stimulus debate
RE
2020Astellas Pharma, Viatris Pharmaceuticals Japan to End Joint Sales Promotion o..
MT
More news
Financials
Sales 2021 1 269 B 12 235 M 12 235 M
Net income 2021 185 B 1 779 M 1 779 M
Net cash 2021 440 B 4 241 M 4 241 M
P/E ratio 2021 16,5x
Yield 2021 2,53%
Capitalization 3 086 B 29 766 M 29 748 M
EV / Sales 2021 2,08x
EV / Sales 2022 1,90x
Nbr of Employees 15 883
Free-Float 99,2%
Chart ASTELLAS PHARMA INC.
Duration : Period :
Astellas Pharma Inc. Technical Analysis Chart | 4503 | JP3942400007 | MarketScreener
Technical analysis trends ASTELLAS PHARMA INC.
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 11
Average target price 2 268,18 JPY
Last Close Price 1 661,50 JPY
Spread / Highest target 117%
Spread / Average Target 36,5%
Spread / Lowest Target -0,69%
EPS Revisions
Managers and Directors
NameTitle
Kenji Yasukawa President, CEO & Representative Director
Yoshihiko Hatanaka Chairman
Naoki Okamura Representative Director & Vice President
Tomokazu Fujisawa Director
Hiroko Sakai Director
Sector and Competitors
1st jan.Capitalization (M$)
ASTELLAS PHARMA INC.4.23%29 742
JOHNSON & JOHNSON1.86%421 997
ROCHE HOLDING AG2.48%305 385
NOVARTIS AG1.97%218 041
MERCK & CO., INC.1.93%210 954
PFIZER INC.-0.30%203 993